Federal Circuit Schedules Oral Argument for Enanta's Paxlovid Patent Appeal Against Pfizer
ENTA has more than doubled off its 52-week low of $4.09.
Summary
Enanta Pharmaceuticals announced that the Federal Circuit has scheduled oral arguments for May 11, 2026, in its patent infringement appeal against Pfizer concerning Paxlovid.
Key Events · Legal and Risk Events · ENTA
-
Oral Argument Scheduled
The U.S. Court of Appeals for the Federal Circuit has scheduled oral arguments for May 11, 2026, in Enanta's appeal against Pfizer.
-
Patent Infringement Lawsuit Update
This update pertains to Enanta's ongoing appeal against Pfizer Inc. for infringement of U.S. Patent No. 11,358,953 related to Paxlovid.
Analysis · ENTA · Life Sciences
This 8-K provides a key procedural update in Enanta's patent infringement lawsuit against Pfizer regarding Paxlovid. The scheduling of oral arguments for May 11, 2026, indicates progress in a high-stakes legal battle that could result in substantial damages for Enanta if successful. Investors should monitor this date closely as the outcome of the appeal could significantly impact the company's financial outlook.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTA was trading at $13.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $353.2M. The 52-week trading range was $4.09 to $17.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.